Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients

Abstract

Atopic dermatitis (AD) is a common, chronic pruritic inflammatory condition, with an estimated prevalence of 15-30% in children, and 2-10% in adults.¹ Pathogenesis of AD is complex, and remains incompletely understood. Th1, Th2 and Th17 have been reported to play a role.² Treatment of severe AD is challenging, with currently licensed systemic agents being limited by adverse effects and suboptimal therapeutic responses.

This article is protected by copyright. All rights reserved.

http://ift.tt/2hgV37t